Asthma treatment by inhalation in young children, or elderly people with poor coordination, is advisable to be made through a Valved Holding Chamber (VHC) device when a pressurized metered-dose inhaler is prescribed. An analysis of the emitted dose (ED) from VHC devices is of utmost importance to infer about the best market option for a certain patient. A full dose Setup was used to test the VHC devices at constant flow and under an inhalation profile. The devices were tested with Ventolin HFA-134a (salbutamol sulphate as API), and the drug deposited in the Setup was recovered with NaOH 0.01M. Solutions concentrations were estimated by UV-Vis spectrophotometry at 244 nm. At constant flow (26 L/min) results unveil that the ED ranking is the following: Vortex® > AeroChamber Plus® > NebuChamber® > SpaceChamber Plus® > OptiChamber Diamond® > A2A Spacer® > Volumatic® > Compact SpaceChamber Plus®. The inhalation profile lead to a different ED ranking: SpaceChamber Plus® > Compact SpaceChamber Plus® > NebuChamber® > AeroChamber Plus® > OptiChamber Diamond® > Vortex® > Volumatic® > A2A Spacer®. Device material, valve design and body length are the most relevant parameters. Evaluation of the emitted Fine Particle Mass is required to provide a meaningful comparison.